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The  essential  oil  from  Croton  polyandrus  Spreng.,  Euphorbiaceae,  leaves  was  tested  for the toxicity  and
antitumor  activity.  The  concentration  producing  50%  hemolysis  was  141  g/ml  on mice  erythrocytes.
In  the  acute  toxicological  study,  the  estimated  LD50 was  447.18  mg/kg.  The  essential  oil  did  not  induce
increase  in  number  of  micronucleated  erythrocytes,  suggesting  low  genotoxicity.  Essential  oil (100  or
150  mg/kg)  showed  signiﬁcant  antitumor  activity  in  Ehrlich  ascitic  carcinoma  model.  We  observed
that  essential  oil  induces  cell-cycle  arrest  at the G0/G1  phase,  and  increases  the  sub-G1  peak,  which
represents  a marker  of  cell  death  by apoptosis.  Survival  also  increased  for the treated  animals.  The  toxi-hrlich ascites carcinoma
ssential oil
enotoxicity
oxicity
cological  analyses  revealed  reduction  in  body  weight,  increased  aspartate  aminotransferase  and  alanine
aminotransferase  activity,  hematological  changes,  and  a thymus  index  reduction.  These  data  suggest  gas-
trointestinal  and  liver  toxicity,  anemia,  leukopenia/lymphocytopenia,  and  immunosuppressive  effects.
Histopathological  analysis  revealed  the  weak  hepatotoxicity  of essential  oil.  In summary,  essential  oil  of
C. polyandrus  displays  in  vivo antitumor  activity  and  moderate  toxicity.
© 2016  Sociedade  Brasileira  de Farmacognosia.  Published  by Elsevier  Editora  Ltda.  This  is  an open
he  CCaccess  article  under  t
ntroduction
Cancer is the one of the leading causes of death in the world, and
t affects millions of people annually (Jain et al., 2011; Hanahan,
014). In this context, the higher plants represent a rich source of
ew substances which may  be useful against tumors (Cragg and
ewman, 2013).
Many studies have been published reporting the diverse thera-
eutic potential of essential oils, including cancer prevention and
reatment. The mechanisms involved include antioxidant, antimu-
agenic and antiproliferative effects, or by enhancing immune
unction and surveillance, inducing enzymes and enhancing detox-
ﬁcation, and modulating multidrug resistance (Bhalla et al., 2013).Many Euphorbiaceae species are recognized in various parts of
he world as being both toxic and medicinal. Croton is a large genus
f Euphorbiaceae, it comprises around 1300 species of trees, shrubs,
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and herbs distributed in tropical and subtropical regions in both
hemispheres (Pereira et al., 2002). Several species of the genus are
aromatic, indicating the presence of volatile constituents (Oliveira
et al., 2001; Lopes et al., 2003).
Essential oils from Croton regelianus,  and C. ﬂavens leaves, as well
as isolated constituents -cadinol, -elemene and -humulene
(Sylvestre et al., 2006; Bezerra et al., 2009) showed in vitro anti-
tumor activity. In vivo studies describe isoguanosine isolated from
C. tiglium, and ascaridole isolated from C. regelianus which have
shown antitumor activity on sarcoma 180 murine model (Kin et al.,
1994; Bezerra et al., 2009).
Croton polyandrus Spreng. is found in Brazil, and is typical of the
semi-arid region, although it also occurs in the Atlantic forest area
of the Brazilian states Alagoas, Bahia, Ceará, Paraíba, Pernambuco,
Piauí, Rio Grande do Norte and Sergipe. Recent studies showed that
extracts and essential oil from C. polyandrous leaves have signiﬁcant
antifungal activity, as well as a weak cytotoxicity against tumor cell
lines (Fernandes et al., 2012; 2013). Some anticancer drugs widely
used in clinical practice, such as cyclophosphamide, have potent
effects in vivo, although they are ineffective in vitro. In general, these
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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ubstances are pro-drugs that must undergo metabolic activation
o produce their effects (Shrivastav et al., 1980; Sun et al., 2006).
Then, the aim of this study was to evaluate the in vivo antitumor
ctivity and toxicity of the essential oil from C. polyandrous leaves
EOC).
aterials and methods
rugs and reagents
5-Fluorouracil (5-FU), Triton X-100, Tween 80, and cyclophos-
hamide were purchased from Sigma–Aldrich (St. Louis, MO,
SA). Dimethylsulfoxide (DMSO) was purchased from Mallinck-
odt Chemicals® (Phillipsburg, NJ, USA). Sodium thiopental
Thiopentax®) was purchased from Cristália (Itapira, SP, Brazil),
nd heparin (Parinex®) from Hipolabor (Sabará, MG, Brazil). Kits
or biochemical and hematological analysis were purchased from
ABTEST® (Lagoa Santa, MG,  Brazil).
lant processing
Croton polyandrus Spreng., Euphorbiaceae, leaves were collected
n February 2011 in Santa Rita, Paraíba State, Brazil. Voucher speci-
ens number Agra & Gois 1446 was deposited at Herbarium Lauro
ires Xavier of the Federal University of Paraíba, Brazil.
xtraction and analysis of essential oil
The fresh leaves of C. polyandrus (500 g) were subjected to
ydrodistillation for 4 h using a Clevenger-type apparatus. The
ssential oil obtained was  dried and analyzed in GC analysis was
erformed on a Shimadzu GC17-A gas chromatograph using fused
ilica capillary column DB-5 (30 m × 0.25 mm id, 0.25 M ﬁlm
hickness). Helium was used as carrier gas at a ﬂow rate of 1 ml/min.
plit ratio 1:100. The oven temperature was programmed from 60
o 240◦ to 3 ◦C/min. The injector and detector temperatures were
20 and 230 ◦C, respectively (Fernandes et al., 2012).
umor cell line
The in vivo antitumor activity of EOC was tested against the
hrlich carcinoma cell line, which was generously provided by
harmacology and Toxicology Division, CPQBA, UNICAMP (Paulínia,
P, Brazil). The cells were maintained in the peritoneal cavities of
wiss mice in the Dr. Thomas George Bioterium (Research Institute
n Drugs and Medicines/Federal University of Paraíba, Brazil).
nimals
Male and female Swiss albino mice (Mus  musculus) obtained
rom the Dr. Thomas George Bioterium (Research Insitute in Drugs
nd Medicines/Federal University of Paraíba, Brazil) were used. The
nimals weighed 28–32 g, and were randomly housed in polyethe-
ene cages in a controlled environment (12 h light/dark cycle,
4 ± 1 ◦C, 55% relative humidity). They were fed on rat chow pellets
nd received water ad libitum. Animals were used in groups of six.
ctions on reducing pain, stress and any suffering were taken in
ccordance with ethical guidelines for animal usage. Experimental
rotocols and procedures were approved by the local animal ethics
ommittee (CEUA-UFPB, no. 0403/12) which follows the interna-
ional principles in ethics for animal experimentation.armacognosia 26 (2016) 751–758
Pharmacological assays
Hemolysis assay
Hemolytic EOC activity was  evaluated using mice erythrocytes
(Kang et al., 2009). Brieﬂy, fresh blood samples were collected, and
re-suspended in PBS to make a 0.5% (v/v) solution. Various concen-
trations of EOC (0–1000 g/ml) dissolved in DMSO (5% v/v in PBS),
were added to the suspension of red blood cells. The plates with the
EOC-erythrocyte mixtures were incubated on a mixer for 60 min
and then centrifuged. The supernatant was carefully removed. After
removal, 200 l of a solution of Triton X-100 (0.1%) was added to
each well containing the EOC-erythrocyte mixtures and thoroughly
stirred. The hemolysis caused was determined by spectrophoto-
metry at 415 nm. The concentration that produces 50% hemolysis
(HC50) was  then determined. Positive control (100% hemolysis),
and negative control (0% hemolysis) incubated erythrocytes with
0.1% Triton X-100 in PBS, and 5% DMSO in PBS, respectively, were
used.
Acute preclinical toxicity study
The evaluation of acute preclinical toxicity for EOC was  per-
formed based on the “Guide for driving of no clinical studies of
toxicology and pharmacological safety required to development of
drugs/Anvisa”, with some modiﬁcations (Anvisa, 2013). Mice (six
males and six females/group) were subjected to single doses of 250,
375, or 500 mg/kg of EOC (intraperitoneally – i.p.)  and the control
group was  administered vehicle alone (5% (v/v) Tween 80 in saline).
The doses levels were chosen based on previous screening. For tox-
icity detection, signs suggestive of central nervous system (CNS),
or autonomic nervous system (ANS) activity were evaluated at the
intervals: 0, 15, 30, and 60 min, after 4 h, and daily for 14 days. Body
weights were registered at the beginning and end of the treatment,
and the animals were observed daily for water and feed consump-
tion. The number of dead animals during the observation period
was counted to determine the dose responsible for the death of
50% of the experimental animals (LD50).
Genotoxicity
For the micronucleus assay, females mice (six/group) were
treated (i.p.) with 150 or 300 mg/kg of EOC. A positive control group
(cyclophosphamide at 50 mg/kg i.p.), and a negative control group
(Tween 80 at 5% in saline), were included. After 48 h, the ani-
mals were anesthetized with sodium thiopental (40 mg/kg), and
peripheral blood samples were collected from the orbital plexus for
making slides. For each animal, three blood smears were prepared,
and a minimum of 2000 erythrocytes were counted to determine
the frequency of micronucleated erythrocytes (OECD, 1997).
In vivo antitumor activity
Seven-day-old Ehrlich carcinoma cells, 0.5 ml
(2.0 × 106 cells/ml) were implanted in the peritoneal cavity of
the female mice (twelve females mice/group) (Chen and Watkins,
1970; Dolai et al., 2012). One day after inoculation, EOC  (100 or
150 mg/kg) was dissolved in 5% (v/v) Tween-80, and administered
for 9 days (i.p.). 5-FU (25 mg/kg) was used as a standard drug.
The healthy group (healthy mice) and tumor control group (mice
bearing Ehrlich ascites carcinoma cells), were treated with 5%
Tween-80 in 0.9% (w/v) NaCl. On the eleventh day, six mice
from each group were kept fasting for 6 h, and peripheral blood
samples were collected from the retro-orbital plexus under light
sodium thiopental anesthesia (40 mg/kg). The animals were then
euthanized and the ascitic ﬂuid was  collected from the peritoneal
ra de Farmacognosia 26 (2016) 751–758 753
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avity. The volume was measured in a graduated centrifuge tube
nd expressed in milliliter. An aliquot was removed for viable cell
ounting by testing with the trypan blue assay (Kiang et al., 2009;
olai et al., 2012).
The remaining animals (n = 6/group) were kept alive with food
nd water ad libitum to calculate the animal’s survival rates.
ell cycle analyses
For the cell cycle analysis, mice (n = 6) inoculated with Ehrlich
scites carcinoma cells were treated with EOC (100 or 150 mg/kg)
or nine days, as described above. One day after the end of the
reatment, ascitic ﬂuid was collected from the peritoneal cavity
nd one million cells were centrifuged at 230 × g for 7 min. The
upernatant was removed, the pellet was resuspended in 0.3 ml
f hypotonic propidium iodide (PI) solution (50 g/ml), and then
ncubated for 4 h at 4 ◦C in the dark. The analysis was  performed by
ytometric ﬂow (BD FACSCalibur®, USA), a total of 10,000 events
ere acquired, and data was analyzed using WinMDI 2.9 software
Maroni et al., 2012).
oxicity in transplanted mice
For the evaluation of possible toxic effects produced by treat-
ent with EOC, the animals were weighed at the beginning and
he end of the treatment (after removing/draining of the residual
scites tumor volume), while daily consumption of water and food
ere evaluated. In addition, the animal organs; liver, spleen, thy-
us, and kidneys were excised, weighed, and the organ indexes
ere then calculated.
Biochemical analyses were performed on serum samples
btained after centrifugation of total blood, at 160 × g for 6 min.
tandardized diagnostic kits were used to determine the levels of
spartate aminotransferase (AST), alanine aminotransferase (ALT),
reatinine, and urea.
The hematological analyses used heparinized whole blood. The
ematological parameters for hemoglobin (Hb) level, red blood cell
RBC) count, hematocrit (Hct), the red blood cell indices; mean
orpuscular volume (MCV), mean corpuscular hemoglobin (MCH),
ean corpuscular hemoglobin concentration (MCHC), and the total
nd differential leukocyte count were determined. The tests were
erformed according to the manufacturer’s instructions.
Livers and kidneys were ﬁxed in 10% (v/v) formaldehyde and
ortions of these organs were cut into small pieces, then into sec-
ions of 5 m,  and stained with hematoxylin–eosin. For detection of
epatic ﬁbrosis, the liver sections were stained with speciﬁc stain
Gordon and Sweet, 1936). Histological analysis was performed by
ight microscopy to determine the presence and extent of liver or
idney lesions.
tatistical analysis
All data are presented as the mean ± S.E.M. The in vitro assays
ere performed in quadruplicate and repeated at least twice.
he HC50 value and their 95% conﬁdence intervals (CI 95%) were
btained by nonlinear regression. The differences between exper-
mental groups were compared by variance analysis (ANOVA), and
ollowed by Tukey’s test (p < 0.05).
esults and discussion
The percentage of identiﬁcation of volatile components of oil
as 86.1%, with a total of 33 identiﬁed components. Monoterpenes
72.7%) and sesquiterpenes (24.2%) were the main groups of chem-
cal constituents isolated, with the majority: p-cymene (12.4%),
ornyl acetate (11%) and ascaridole (6.4%). This is in accordanceFig. 1. Percentage of hemolysis in red blood cells of Swiss mice upon treatment with
EOC  (g/ml). Each dot represents the average ± SEM of three experiments with three
replicates, with a 95% conﬁdence interval.
with what was  previously published for essential oil from Croton
polyandrous leaves (Fernandes et al., 2012). In addition, the chemi-
cal composition presented here was  consistent with literature data
for volatile constituents of other Croton species (Sylvestre et al.,
2006; Bezerra et al., 2009; Correa-Royero et al., 2009).
The hemolytic activity assay with erythrocytes of Swiss mice
was performed to evaluate non-tumor cell toxicity. After treat-
ment with EOC, the percentage of hemolysis increased in a
concentration-dependent manner. The HC50 value obtained was  in
the range of 141.0 (140.5–141.6) g/ml (Fig. 1).
Anemia is the most common hematological cancer manifes-
tation, and its incidence increases with the administration of
chemotherapy/radiotherapy. The red blood cells and hemoglobin
may  be decreased through destruction and/or the inability of the
bone marrow to make these cells (Gaspar et al., 2015).
The data showed that EOC had moderate cytotoxicity against
mice erythrocytes, inducing 100% of hemolysis from 250 g/ml.
This corroborates ﬁndings in the literature which indicate that cer-
tain essential oils and/or compounds isolated from plants can affect
cell membrane structures and produce hemolysis (Ng et al., 1986;
Grinberg et al., 1997; Zhang et al., 1997; Wu et al., 2012; Rodrigues
et al., 2013). Nevertheless, recent data showed that EOC is not cyto-
toxic to non-tumor cells of the CHO (ovarian), and HaCaT (human
keratinocyte) lines (Fernandes et al., 2012).
The acute treatment with EOC induced death in male and female
mice only at 375 and 500 mg/kg (Table 1). The LD50 value obtained
was approximately 447.18 mg/kg. It was observed that in the ﬁrst
few moments following administration of EOC (0, 15, 30 min) the
animals showed severe CNS stimulant effects such as hyperactivity,
being more pronounced at the higher doses. At 4 h after adminis-
tration, we contradictorily observed CNS depressant effects such
as decreased touch response, loss of corneal and sound reﬂexes,
and ptosis. The occurrence of ptosis is described in some classes of
depressant drugs such as neuroleptics and analgesics central action.
Already the reduction or loss of pain reﬂex suggests an antinoci-
ceptive activity. There were also observed effects on the ANS,
including forced breathing and diarrhea, which suggest parasym-
pathetic stimulation (Carlini, 2003; Almeida et al., 2001). However,
these effects disappeared after 4 h of treatment. Literature data
reported that, in general, if the lethal dose (LD50) of the test sub-
stance is three times more than the minimum effective dose, the
substance is considered a good candidate for further studies (Carol,
1995; Amelo et al., 2014).
There was  a signiﬁcant decrease in water and feed consump-
tion for most groups treated with EOC, as compared to the control
group (Table 2). In relation to body weight, the signiﬁcant decrease
was observed only in male mice. These parameters could not be
evaluated at a dose of 500 mg/kg, due to the deaths of the experi-
mental animals.
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Table 1
Effect of single doses (i.p.) of EOC in mice (n = 6).
Dose (mg/kg) Sex M/T  Symptoms
– M 0/6 None
F 0/6 None
250
M 0/6 Hyperactivity
F 0/6 None
375
M 2/6 Hyperactivity, ptosis, labored breathing, decreased response to touch, loss of corneal reﬂex,
loss of sound reﬂex
F  1/6 Hyperactivity, ptosis, labored breathing, decreased response to touch, loss of corneal reﬂex,
loss of sound reﬂex
500
M  5/6 Hyperactivity, ptosis, ataxia, labored breathing, decreased response to touch, loss of corneal
reﬂex, loss of sound reﬂex, abduction of the hind paws, diarrhea
F  3/6 Hyperactivity, ptosis, ataxia, labored breathing, decreased response to touch, loss of corneal
reﬂex, loss of sound reﬂex, abduction of the hind paws, diarrhea
M/T, number of dead mice/number of treated mice.
Table 2
Feed and water consumption and weight of animals (n = 6) subjected to acute treatment with EOC (250 or 375 mg/kg).
Group Sex Dose, mg/kg Water consumption, ml  Feed intake, g Initial weight, g Final weight, g
Control
M – 46.92 ± 1.45 40.72 ± 0.63 31.22 ± 0.57 37.68 ± 1.68
F  39.38 ± 0.71 34.42 ± 0.97 30.45 ± 0.84 33.85 ± 0.70
EOC
M
250
38.85 ± 1.01a 35.69 ± 1.21a 28.45 ± 0.92 30.03 ± 1.05a
F 32.08 ± 0.89a 34.16 ± 1.43 27.52 ± 1.05 32.67 ± 0.88
EOC
M
375
33.08 ± 2.16a 27.43 ± 0.93a 30.65 ± 0.96 29.55 ± 2.56a
F 26.15 ± 1.28a 25.28 ± 1.99a 29.02 ± 0.92 32.84 ± 0.63
Data presented as a mean ± SEM of six animals analyzed by ANOVA followed by Tukey te
a p < 0.05 compared to control.
Table 3
Number of micronucleated erythrocytes in peripheral blood of mice treated with
single doses of EOC and cyclophosphamide (n = 6).
Groups Dose, mg/kg Number of micronucleated cells
Control – 2.80 ± 0.37
Cyclophosphamide 50 14.50 ± 2.60a
EOC 150 2.20 ± 0.37
EOC 300 2.40 ± 0.25
D
b
(
a
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w
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E
Data are presented as SEM of the mean of six animals analyzed by ANOVA followed
y Tukey test.
a p < 0.05 compared to the control group with ANOVA, and followed by Tukey.
Almost all anticancer drugs cause gastrointestinal disorders
Boussios et al., 2012). In this context, metabolic parameters, such
s weight, and feed intake assessments must be evaluated dur-
ng preclinical studies to investigate general toxicity. Then, the
ecrease on water and feed consumption, and decrease on body
eight induced by EOC demonstrate all together toxicity.
The preclinical toxicological evaluation allowed determining
he safe pharmacological doses to proceed with in vivo pharma-
ological studies.
To evaluate in vivo genotoxic effects of EOC we performed
icronucleus testing (Table 3). Animals treatment with EOC did not
nduce increases in the number of micronucleated erythrocytes in
eripheral blood as compared to the control group. Then, the results
id not show genotoxic effects for EOC, in this experimental model.
able 4
ffects of 5-FU and EOC on cell viability and tumor volume in mice (n = 6) transplanted w
Groups Dose, mg/kg Cell 
Tumor control – 219
5-FU  25 2.9
EOC 100 4.8
EOC 150 3.9
ata presented as mean ± SEM of six animals analyzed by ANOVA followed by Tukey test
a p < 0.05 compared to tumor control.st.
Plants produce a wide variety of substances, which may have ther-
apeutic importance; however, many of them may have mutagenic
effects. In addition, many anticancer drugs can cause side effects
that include induction of genotoxicity in non-tumor cells (Vieira
et al., 2010).
For in vivo antitumor activity assay, we used Ehrlich ascites car-
cinoma cells. This cell line is referred to as an undifferentiated
carcinoma, and is originally hyperdiploid, has high transplantable
capability, no-regression, rapid proliferation, shorter life span,
100% malignancy and also does not have tumor speciﬁc transplan-
tation antigen (TSTA) (Ozaslan et al., 2011). Therefore, an excellent
model for studying experimental neoplasia (Salgado et al., 2002;
Nascimento et al., 2006; Verc¸ osa Júnior et al., 2006; Araújo et al.,
2009). The analyzed parameters (tumor volume, and cell viabil-
ity) signiﬁcantly decreased compared to the tumor control group,
featuring a tumor growth inhibitory activity in both doses tested
of EOC (100 or 150 mg/kg). There was no signiﬁcant difference in
the parameters between the groups treated with the EOC and 5-FU
(Table 4).
Some of the constituents present in EOC are described in
the literature as having signiﬁcant antitumor activity, speciﬁ-
cally ascaridole (Bezerra et al., 2009), limonene (Gould, 1997),
-humulene (Silva et al., 2008), terpinen-4-ol (Wu et al., 2012),
caryophyllene (Zheng et al., 1992), 1,8-cineole, -pinene and -
pinene (Wang et al., 2012). Nevertheless, a recent review of the
anticancer activity of essential oils reported that the theory of
ith Ehrlich ascites carcinoma cells subjected to different treatments (9 days).
viability, ×106 cells/ml Tumor volume, ml
.8 ± 27.77 9.34 ± 1.40
9 ± 0.96a 0.09 ± 0.02a
5 ± 1.28a 0.10 ± 0.02a
5 ± 0.49a 0.04 ± 0.02a
.
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Table  5
Feed and water consumption and weight of animals (n = 6) subjected to different treatments (9 days).
Groups Dose, mg/kg Water consumption, ml  Feed consumption, g Initial weight, g Final weight, g
Healthy animals – 35.67 ± 1.12 30.85 ± 1.57 28.62 ± 0.37 32.27 ± 0.86
Tumor  control – 34.69 ± 2.16 29.33 ± 1.45 27.74 ± 1.20 31.02 ± 1.10
5-FU  25 33.44 ± 1.57 32.84 ± 1.21 27.56 ± 0.62 25.78 ± 0.35a,b
EOC 100 32.19 ± 2.70 24.41 ± 0.88a,b 27.90 ± 1.31 26.88 ± 0.94a,b
EOC 150 24.38 ± 1.70a,b 15.49 ± 1.17a,b 29.30 ± 0.86 24.34 ± 0.93a,b
Data presented as mean ± SEM of six animals analyzed by ANOVA followed by Tukey test.
a p < 0.05 compared to tumor control.
b p < 0.05 compared to healthy animals.
Table 6
Effects of 5-FU and EOC on the mice organ indices (n = 6) subjected to different treatments (9 days).
Groups Dose, mg/kg Heart index, mg/g Liver index, mg/g Kidneys index, mg/g Thymus index, mg/g Spleen index, mg/g
Healthy animals – 4.22 ± 0.25 50.83 ± 2.07 10.85 ± 0.47 3.73 ± 0.54 5.54 ± 0.46
Tumor  control – 3.86 ± 0.12 69.42 ± 4.04 13.17 ± 0.59 2.61 ± 0.15 6.19 ± 0.28
5-FU  25 4.84 ± 0.48 57.39 ± 1.92 12.29 ± 0.30 2.85 ± 0.08 6.32 ± 0.51
EOC  100 4.38 ± 0.15 64.35 ± 4.09 13.15 ± 0.64 2.88 ± 0.60 7.12 ± 0.98
EOC  150 4.73 ± 0.31 62.35 ± 5.46 14.55 ± 0.32 1.84 ± 0.13a 5.49 ± 0.83
Data presented as mean ± SEM of six animals analyzed by ANOVA followed by Tukey test.
a p < 0.05 compared to healthy animals.
Table 7
Effects of 5-FU and EOC on biochemical parameters of peripheral blood of mice (n = 6) subjected to different treatments (9 days).
Groups Dose, mg/kg AST, U/L ALT, U/L Urea, mg/dL Creatinine, mg/dL
Healthy animals – 283.2 ± 24.94 53.6 ± 6.55 39.0 ± 1.87 0.42 ± 0.08
Tumor  control – 287.8 ± 20.19 71.8 ± 7.31 66.0 ± 11.64 0.46 ± 0.04
5-FU  25 242.0 ± 12.17 67.8 ± 7.11 43.0 ± 7.14 0.32 ± 0.02
EOC  100 348.0 ± 32.35 54.0 ± 8.50 52.8 ± 16.86 0.63 ± 0.15
EOC  150 405.2 ± 24.43a,b 240.8 ± 27.88a,b 30.6 ± 4.41 0.60 ± 0.02
D y test.
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Fig. 2. Percentage of Ehrlich ascites carcinoma cells in different phases of the cell
cycle after treatment with 5% Tween 80 solution (control), EOC  (100 mg/kg), EOC
(150 mg/kg) and 5-FU (25 mg/kg), ap < 0.05 compared to control group, bp < 0.05ata presented as mean ± SEM of six animals analyzed by ANOVA followed by Tuke
a p < 0.05 compared to tumor control.
b p < 0.05 compared to healthy animals.
ynergistic action appears to be a signiﬁcant aspect, emphasiz-
ng the importance to study the whole essential oil rather than its
omponents separately (Bhalla et al., 2013).
One of the main ways to study the mechanism of action of anti-
ancer drugs is to examine if the drug exerts its effects by inducing
ell cycle arrest. EOC induced signiﬁcant change in the distribu-
ion of Ehrlich carcinoma cells in different cell cycle phases. There
ere increases in the percentage of cells in G0/G1, and simulta-
eous reduction of cells in the S phase, and in the G2/M phase. In
ddition, we observed a signiﬁcant increase in the content of sub-
iploid DNA (fragmented DNA) in the cells of animals treated with
OC (Fig. 2), which is considered as a marker of cell death by apo-
tosis (Darzynkiewicz et al., 1992). Induction of apoptosis is one
he most important marker of cytotoxic antitumor agents. It has
een shown that some natural compounds including plants induce
poptotic pathways that are blocked in cancer cells (Safarzadeh
t al., 2014).
Considering the various toxic side effects of anticancer agents
n normal cells, we proceeded to investigate possible EOC toxic-
ty. EOC induced a decrease in water and feed consumption when
ompared to the healthy and tumor control groups (Table 5). We
ound a signiﬁcant decrease in the ﬁnal weights for all of the animals
reated, including those treated with 5-FU. The results corroborate
he data observed on acute toxicity study, conﬁrming the possible
astrointestinal EOC toxicity. Similarly, 5-FU also induced a reduc-
ion in body weight that was expected since this is an effect well
escribed in the literature for this chemotherapy (El-Sayyad et al.,
009).
In regarding to the organ indexes, there was  a signiﬁcant
ecrease in the thymus index for the group treated with EOC
150 mg/kg) compared to the healthy group (Table 6). The datacompared to group treated with 5-FU with ANOVA and then followed by the Tukey
test.
for the thymus index indicate that EOC promoted an apparent
immunosuppression, which corroborates with the hematological
data showing a decrease in lymphocytes after treatment with the
highest EOC dose. This effect is one of the most common side effects
of chemotherapeutic agents currently used in clinical practice
(Rasmussen and Arvin, 1982).No signiﬁcant changes were observed for either urea or cre-
atinine levels, suggesting no renal toxicity. For liver enzymes,
signiﬁcant increases in AST and ALT enzymatic activity for the
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100  mg/kg); (C) Kupffer cell hyperplasia – EOC (150 mg/kg); (D) moderate increa
olyploidy phenomena – 5-FU (25 mg/kg).
roup treated with EOC (150 mg/kg), in relation to the tumor con-
rol and healthy groups, was observed (Table 7). The data suggest
hat EOC induced liver toxicity, as evidenced by increased AST, but
ore importantly by the increase in ALT. Signiﬁcantly, we observed
hat the changes were not within normal variation limits for mice
nzymatic activity (reference values: AST – for male and female
ice, 70–400 IU/l, ALT – for males, 25–200 IU/l and for females,
5–100 IU/l) (Gad, 2007).
In the hematological evaluations, EOC (150 mg/kg) induced a
igniﬁcant decrease in the red blood cell count, hemoglobin and
ematocrit (Table 8). In addition, signiﬁcant increase was observed
or MCV  and MCH  (Table 8). This suggests clinical features of ane-
ia  (Nissenson et al., 2003). This complication is common for many
atients in chemotherapy (Gaspar et al., 2015) and these results
orroborate the data observed on hemolytic assay, conﬁrming
he toxicity of the oil to erythrocytes. Based on hematimetric
ndices, we suggest that the anemia caused by treatment with EOC
150 mg/kg) ﬁts the macrocytic and normochromic anemia pro-
le.
The leukopenia and lymphocytopenia observed for EOC
150 mg/kg) is one of the major side effects of cancer treatment,
rug aggression toward cells of the immune system (Liu et al.,
013). Yet, it was possible to demonstrate a marked leukopenia,
ith increase of lymphocytes and reduction of neutrophils in the
reatment with 5-FU (Table 8), known side effects of this anticancer
rug (Lins et al., 2009).iar triad and hepatic cords lobular – control; (B) parenchymal necrosis foci – EOC
 the number of lymphocytes in portal areas – 5-FU (25 mg/kg); (E) hepatocellular
No histopathological changes were observed in the kidneys of
animals treated with EOC (data not shown). In the majority of ani-
mals treated with both doses of EOC we  observed liver changes
such as Kuppfer cell hyperplasia, moderate increases in the num-
ber of lymphocytes in portal areas, and parenchymal necrosis foci
(randomly seen in zones I, II and III) (Fig. 3B and C). In the ani-
mals of 5-FU group, beyond these changes, we  found peri-portal
inﬂammation, peri-septal necrosis featuring discrete (piecemeal)
areas of hepatic cytolysis, inﬂammation within the portal spaces,
parenchymal activity, with focal hepatocyte necrosis surrounded
by lymphohistiocytic aggregates in many places, and hepatocellu-
lar polyploidy phenomena (Fig. 3D and E). In the treatment group
(5-FU), the histological changes were consistent with moderately
active toxic hepatitis.
The data corroborate the biochemical results obtained for AST
and ALT for the highest dose (150 mg/kg) of EOC. However, all of
the changes common to both treated groups are reported in the
literature as evidence of weak hepatotoxicity. Withdrawal of the
drug, or a dosage adjustment usually leads to a rapid improvement
and reversal of the damage (Torti et al., 2001; Montenegro et al.,
2008).
There was  a signiﬁcant increase in survival time of all of groups,
when compared with the tumor control group (Fig. 4), however
more pronounced at 100 mg/kg of EOC. Considering that there was
no signiﬁcant difference in the effect of 100 or 150 mg/kg of EOC
in the parameters tumor volume and cell viability, and that the
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Table  8
Effects of 5-FU and EOC on hematological parameters of peripheral blood of mice (n = 6) subjected to different treatments (9 days).
Parameters Healthy animals Tumor control 5-FU EOC
25 mg/kg 100 mg/kg 150 mg/kg
Red blood cells, 106/mm3 9.36 ± 0.14 8.20 ± 0.50 8.48 ± 0.16 8.79 ± 0.23 6.21 ± 0.74a,b
Hemoglobin, g/dl 14.84 ± 0.24 12.50 ± 0.80 12.88 ± 0.08 14.14 ± 0.17 10.46 ± 0.18b
Hematocrit, % 43.84 ± 0.55 40.76 ± 2.38 37.32 ± 1.01 40.40 ± 0.69 34.22 ± 4.07b
MCV, fm3 46.60 ± 0.97 49.60 ± 0.25 43.80 ± 0.58a,b 46.00 ± 0.84a 54.80 ± 0.20a,b
MCH, pg 15.84 ± 0.47 15.26 ± 0.19 15.22 ± 0.23 16.14 ± 0.26 16.88 ± 0.24a
MCHC, g/dl 33.74 ± 0.38 30.68 ± 0.28 34.52 ± 0.83 34.04 ± 0.52 32.62 ± 1.79
Total  leukocytes, 103/mm3 8.18 ± 0.43 13.66 ± 1.0 4.12 ± 0.59a 10.86 ± 2.87 4.86 ± 1.0a
Lymphocytes, % 60.60 ± 4.24 36.20 ± 6.53b 78.40 ± 2.21a 41.40 ± 8.48 24.23 ± 2.88a,b
Neutrophils, % 34.60 ± 4.21 54.20 ± 9.22 17.40 ± 2.5a 64.0 ± 6.63b 63.40 ± 5.5b
Monocytes, % 4.40 ± 0.74 4.20 ± 1.2 3.40 ± 0.75 4.0 ± 1.13 5.60 ± 1.12
Eosinophils, % 0.40 ± 0.24 0.29 ± 0.20 0.40 ± 0.24 0.22 ± 0.11 0.60 ± 0.40
Data are presented as mean ± SEM of six animals analyzed by ANOVA followed by Tukey 
a p < 0.05 compared to tumor control.
b p < 0.05 compared to healthy animals.
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nig. 4. Survival times of female mice inoculated with Ehrlich carcinoma cells and
reated with EOC and 5-FU. Data presented as mean ± SEM of six animals analyzed
y  Kaplan–Meier test.
bserved toxicity to treatment with 100 mg/kg was signiﬁcantly
ower, we have shown the advantages of EOC at a dose of 100 mg/kg.
onclusions
EOC has potent in vivo antitumor activity, and induces moderate
astrointestinal, hematological and liver toxicity, under the condi-
ions evaluated. Nevertheless, it does not represent a limiting factor
or the continuity of pre-clinical pharmacological studies, whereas
ntineoplastic drugs typically exhibit high toxicity.
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